Endocrine Abstracts

Contents

• Speaker Abstracts
• • Endocrinology, Diabetes & Metabolism Case Reports Session
  • • EDM Case Reports Session

      ea0068nets1.1
  • Daily Clinical dilemmas in NEN & NEN disease from patients’ perspective
  • • Holistic care for NEN patients: updates from the NET Patient Foundation, Mrs Catherine Bouvier (NPF)

      ea0068nets2.1
    • Abstract unavailable

      ea0068nets2.2
    • Abstract unavailable

      ea0068nets2.3
    • Abstract unavailable

      ea0068nets2.4
    • Abstract unavailable

      ea0068nets2.5
  • Optimal surgical approach for GEP-NEN in 2019
  • • Abstract unavailable

      ea0068nets3.1
    • Abstract unavailable

      ea0068nets3.2
    • Abstract unavailable

      ea0068nets3.3
    • Rectal NEN: do we really need the Surgeons?

      ea0068nets3.4
  • Translational Medicine
  • • Abstract unavailable

      ea0068nets4.1
    • Evaluation of somatostatin analogue-JQ1 conjugates for the treatment of pancreatic neuroendocrine tumours

      ea0068nets4.2
    • Abstract unavailable

      ea0068nets4.3
  • Liver Transplantation for NEN
  • • Abstract unavailable

      ea0068nets5.1
    • Abstract unavailable

      ea0068nets5.2
    • Intratumour Heterogeneity and tumour evolution in neuroendocrine cancers of the lung

      ea0068nets5.3
  • Updates in Clinical Trials
  • • Abstract unavailable

      ea0068nets6.1
• Oral Communications
• • Abstracts
  • • Longitudinal biomarker changes during treatment of functional midgut neuroendocrine tumours with lanreotide autogel: CALM-NET study results

      ea0068oc1
    • Development of ex-vivo models of metastatic neuroendocrine neoplasms

      ea0068oc2
    • Incidence and prevalence of neuroendocrine neoplasms reported in England from 2015 to 2017

      ea0068oc3
• Poster Presentations
• • Abstracts
  • • Size still matters for appendiceal neuroendocrine tumours (aNETs)

      ea0068p1
    • The role of Thymosin Beta 4 as an autocrine mitogen in neuroendocrine tumours

      ea0068p2
    • The effects of somatostatin analogues on HbA1c and BMI in the treatment of neuroendocrine tumours

      ea0068p3
    • Appendiceal GCCs have a poor prognosis despite completion surgery as recommended by ENET guidelines

      ea0068p4
    • Development of a mobile app for patients with neuroendocrine neoplasms: a collaborative project between United Kingdom NET Society and Neuroendocrine Tumour Patient Foundation

      ea0068p5
    • Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms: experience from a European Neuroendocrine Tumour Society centre of excellence

      ea0068p6
    • pNETs (Pancreatic Neuroendocrine tumours) in MEN1 (Multiple Endocrine Neoplasia): a single centre case series

      ea0068p7
    • Audit of the appropriateness and outcomes of 24-hour urinary 5-HIAA testing in a UK general hospital

      ea0068p8
    • Gastric neuroendocrine neoplasms: clinical management and outcomes in a cohort of 54 patients

      ea0068p9
    • Type III gastric neuroendocrine neoplasms: moving towards less-extensive resections in selected cases?

      ea0068p10
    • Can determination of radiological tumour volumes and tumour growth rates better determine response to somatostatin analogues in slowly growing neuroendocrine tumours?

      ea0068p11
    • Systemic chemotherapy for inoperable Goblet Cell Adenocarcinomas (GCAs)

      ea0068p12
    • Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome: a single centre study from a centre of excellence

      ea0068p13
    • Liver embolisation for patients diagnosed with neuroendocrine neoplasms: systematic review and meta-analysis of the literature

      ea0068p14
    • Surgical correction of carcinoid heart disease improves liver function, 5HIAA levels and subjective assessment of carcinoid symptoms

      ea0068p15
    • Clinical characteristics and outcomes of 23 patients with insulinoma: a single centre retrospective observational study 2011-2018

      ea0068p16
    • Single Centre Experience of PRRT with ⁹⁰Y DOTATATE in metastatic or unresectable paragangliomas

      ea0068p17
    • Frequency and causes of elevated fasting plasma concentrations of a panel of gut hormones in routine clinical practice

      ea0068p18
    • Endoscopic management and outcomes of gastro-duodenal neuroendocrine tumours

      ea0068p19
    • A retrospective study of FDG uptake in pathologically confirmed DIPNECH and its contributing variables

      ea0068p20
    • Mitotane treatment in adrenocortical cancer: getting to and staying in the therapeutic range, toxicity and outcomes

      ea0068p21
    • Sheffield experience of administering Lutathera as a day case treatment

      ea0068p22
    • Effects of debulking surgery, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) on quality of life in patients with metastatic ileal and pancreatic neuroendocrine tumours (NETs)

      ea0068p23
    • Improving diagnosis times as part of the transformation of the South Wales NET Service

      ea0068p24
    • (Non)Functioning neuroendocrine tumours in 18F-FDG PET-CT

      ea0068p25
    • The incidence of additional primary malignancies in patients with GEP-NETs

      ea0068p26
    • The impact of telotristat in the west and east of Scotland

      ea0068p27
    • Paraganglioma in a patient with cyanotic congenital heart disease

      ea0068p28
    • Normal patterns of pancreatic uptake on 68Ga-DOTA PETCT

      ea0068p29
    • Nutrition in patients with gastro-entero-pancreatic (GEP) neuroendocrine tumours (NETs) and NETs of unknown primary

      ea0068p30
    • Transformation of non-functional metastatic pancreatic neuroendocrine tumour to functional insulinoma; a rare but recognised phenomenon

      ea0068p31
    • A rare case of a left atrium paraganglioma - case report

      ea0068p32
    • Confusion in a patient with Carcinoid syndrome

      ea0068p33
    • Neuroendocrine breast metastases: difficulties in interpretation of pathology and distinction from breast cancer

      ea0068p34
    • How does exercise affect the quality of life in cancer patients? A literature review

      ea0068p35
    • Two case reports of preserved endocrine and exocrine function in VHL patients with extensive pancreatic cysts

      ea0068p36
    • Practicality of setting up a Lutetium peptide therapy service

      ea0068p37